Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Smith

Showing results (151-160 of 172) with videos related to

Pageof 18
Sort By:
Nature Communications|November 2, 2025
Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapiesElizabeth J Carstens, Kazuki Takahashi, Naoya Sakamoto, et al.
Transplantation and Cellular Therapy|May 23, 2022
Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple MyelomaSarah A Holstein, Fotis Asimakopoulos, Abdel Kareem Azab, et al.
Cell Reports. Medicine|June 21, 2025
Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platformYuqing Zhang, Zehua Li, Jessica Ritter, et al.
Nature Communications|February 10, 2025
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's MacroglobulinemiaRomanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, et al.
Molecular Therapy. Methods & Clinical Development|September 13, 2021
Depletion of high-content CD14<sup>+</sup> cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturingXiuyan Wang, Oriana Borquez-Ojeda, Jolanta Stefanski, et al.
Eclinicalmedicine|March 10, 2023
Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort studyNeha Korde, Elizabet Tavitian, Donna Mastey, et al.
Blood|July 7, 2026
Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myelomaSham Mailankody, Sneha Mitra, Kevin Herrera, et al.
American Journal of Hematology|March 4, 2021
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m<sup>2</sup> ) in combination with lenalidomide and dexamethasoneNeha Korde, Donna Mastey, Elizabet Tavitian, et al.
Science Translational Medicine|March 29, 2019
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cellsEric L Smith, Kim Harrington, Mette Staehr, et al.
Blood Cancer Discovery|October 18, 2021
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic CentersMalin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.
Pageof 18

Showing results (151-160 of 172) with videos related to

Sort By:
Pageof 18
Nature Communications|November 2, 2025
Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapiesElizabeth J Carstens, Kazuki Takahashi, Naoya Sakamoto, et al.
Transplantation and Cellular Therapy|May 23, 2022
Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple MyelomaSarah A Holstein, Fotis Asimakopoulos, Abdel Kareem Azab, et al.
Cell Reports. Medicine|June 21, 2025
Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platformYuqing Zhang, Zehua Li, Jessica Ritter, et al.
Nature Communications|February 10, 2025
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's MacroglobulinemiaRomanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, et al.
Molecular Therapy. Methods & Clinical Development|September 13, 2021
Depletion of high-content CD14<sup>+</sup> cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturingXiuyan Wang, Oriana Borquez-Ojeda, Jolanta Stefanski, et al.
Eclinicalmedicine|March 10, 2023
Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort studyNeha Korde, Elizabet Tavitian, Donna Mastey, et al.
Blood|July 7, 2026
Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myelomaSham Mailankody, Sneha Mitra, Kevin Herrera, et al.
American Journal of Hematology|March 4, 2021
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m<sup>2</sup> ) in combination with lenalidomide and dexamethasoneNeha Korde, Donna Mastey, Elizabet Tavitian, et al.
Science Translational Medicine|March 29, 2019
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cellsEric L Smith, Kim Harrington, Mette Staehr, et al.
Blood Cancer Discovery|October 18, 2021
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic CentersMalin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.
Pageof 18